Anavex reports Q3 EPS (14c), consensus (17c)

“We are very excited to be entering an important phase of the Company, with several key data readouts based on innovative science at Anavex with ANAVEX2-73, an orally available, small-molecule activator of the upstream sigma-1 receptor, involved in restoring neural cell homeostasis and promoting neuroplasticity,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “We remain focused on execution as we prepare for a pivotal year ahead of us potentially involving a digital ‘Healthcare Sales Marketing’ pharma platform and also making meaningful advances in our other neurodevelopmental and neurodegenerative precision medicine portfolio, including schizophrenia and Parkinson’s disease.”